![Christopher Henney](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Henney
Director/Board Member at CYCLACEL PHARMACEUTICALS, INC.
Net worth: 10 795 $ as of 31/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul McBarron | M | 63 | 22 years | |
M. Wilsey | M | 71 | 15 years | |
Samuel Barker | M | 81 | 10 years | |
Brian Schwartz | M | 52 | 4 years | |
Spiro Rombotis | M | 65 | 27 years | |
Karin Walker | F | 60 | 11 years | |
Kenneth Ferguson | M | 68 |
ICOS Corp.
![]() ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 20 years |
Michael J. Malecek | M | 58 | 5 years | |
Paula Cobb | F | 51 | 5 years | |
Brandon Smith | M | 50 | 4 years | |
Robert Spiegel | M | 73 | 6 years | |
Oleg Nodelman | M | 47 | 5 years | |
Hans Lennart Rudolf Wigzell | M | 86 | 14 years | |
Dennis Selkoe | M | 80 | 11 years | |
Carol Karp | F | 71 | 8 years | |
Hideki Garren | M | 60 | 3 years | |
Yvonne M. Tchrakian | F | - | 10 years | |
Michael Bachner | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Dan Spiegelman | M | 65 |
Xcyte Therapies, Inc.
| 15 years |
Edward A. Taylor | M | 81 |
Biomira, Inc.
![]() Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 13 years |
George B. Rathmann | M | - |
ICOS Corp.
![]() ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 11 years |
Robert L. Kirkman | M | 75 |
Biomira, Inc.
![]() Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 10 years |
Bogdan Dziurzynski | M | 75 | 14 years | |
Mitchell Gold | M | 57 | 12 years | |
Julia Eastland | F | 59 | 14 years | |
Richard L. Jackson | M | 84 |
Biomira, Inc.
![]() Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 14 years |
Douglas G. Watson | M | 79 | 15 years | |
S. Robert Blair | M | - |
Biomira, Inc.
![]() Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 15 years |
David C. U'Prichard | M | 75 | 16 years | |
Dale B. Schenk | M | 66 | 4 years | |
May Liu | F | 48 | 11 years | |
Scott Myers | M | 57 | 2 years | |
Leslie Hudson | M | 76 | 2 years | |
Nancy Whiting | M | 51 | - | |
W. Vickery Stoughton | M | 78 |
Biomira, Inc.
![]() Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 18 years |
Douglas Williams | M | 66 | 4 years | |
Gary W. Christianson | M | 69 |
Biomira, Inc.
![]() Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 11 years |
Anthony Chase | M | 69 | - | |
Brian Mueller | M | 50 | 6 years | |
Shashi Karan | M | 70 | 2 years | |
Mark E. Kaufmann | M | 56 |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 5 years |
Karl Härfstrand | M | 66 | 9 years | |
David Thompson | M | 76 | - | |
Martin Simonetti | M | 66 | 6 years | |
K. Michael Forrest | M | 80 | 5 years | |
Christopher Lowe | M | 56 | 6 years | |
R. Rao Koganty | M | 81 |
Biomira, Inc.
![]() Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 22 years |
Ronald Berenson | M | - | 10 years | |
Ursula Fritsch | M | 64 | - | |
Rachel Leheny | M | 60 | 3 years | |
Colin Hislop | M | 66 | 11 years | |
Sylvain Chemtob | M | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 8 years |
Christiane Quiniou | M | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 8 years |
Diana Hausman | M | 61 | 7 years | |
Paula Adams | M | 61 | - | |
Sanjiv Patel | M | 50 | 2 years | |
Jennifer Zibuda | F | - | 3 years | |
Philip T. Sager | M | 68 | 5 years | |
T. McPherson | M | 85 |
Biomira, Inc.
![]() Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 15 years |
Gerardo Canet | M | 78 | 17 years | |
Steven Engle | M | 69 | 3 years | |
Steven James | M | 66 | 3 years | |
Arthur William Homan | M | 64 | 5 years | |
Judy Chiao | M | 64 | 17 years | |
D. Kirkpatrick | M | 67 |
Biomira, Inc.
![]() Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 2 years |
Gregory Hradsky | M | 63 | - | |
Tara Nickerson | M | 51 | 6 years | |
Susan B. Bayh | F | 64 | 12 years | |
James Healy | M | 59 | 8 years | |
Peter Thompson | M | 64 | 2 years | |
David L. Urdal | M | 74 | 20 years | |
Frank Valone | M | 74 | 8 years | |
Gary L. Wilcox | M | 77 |
ICOS Corp.
![]() ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 14 years |
Ted Love | M | 65 | 5 years | |
John Banham | M | 83 | 14 years | |
Debra A. Odink | M | 60 | 11 years | |
Donald Santel | M | 62 | 5 years | |
Lloyd Sems | M | 52 | - | |
Michael C. Welsh | M | 81 |
Biomira, Inc.
![]() Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 21 years |
Joanna Lin Black | F | - |
Xcyte Therapies, Inc.
| 3 years |
Sanford Zweifach | M | 68 | 3 years | |
Nicholas Bacopoulos | M | 75 | 8 years | |
Peter van Vlasselaer | M | 64 | 6 years | |
Charles Olson | M | 66 | 7 years | |
Mark Kirschbaum | M | 63 | 4 years | |
Amartya Basu | M | - | 3 years | |
Curtis L. Ruegg | M | 61 | 5 years | |
Nikhil Agarwal | M | - | 3 years | |
Shing-Yin Tsui | F | 53 | 16 years | |
Robert Fishman | M | 62 | 2 years | |
Klara Dickinson-Eason | F | 57 | 2 years | |
Ela Borenstein | F | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 4 years |
Brian Blackman | M | - | 4 years | |
John Womelsdorf | M | 60 | 3 years | |
M. Blake Ingle | M | 81 | 6 years | |
Stewart Craig | M | 63 |
Xcyte Therapies, Inc.
| 6 years |
Shawn Barney | M | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | - |
Robert Sosnowski | M | 64 | 4 years | |
Clifford Stocks | M | - |
ICOS Corp.
![]() ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | 19 years |
Gregory Reyes | M | 70 | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 79 | 79.00% |
Ireland | 16 | 16.00% |
Canada | 15 | 15.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christopher Henney
- Personal Network